May 29 Preclinical Quick Takes: Vor debuts lead stem cell program; plus an inverse Alzheimer's-cancer target, and statins for cognitive defects

Vor Biopharma unveils lead candidate comprising CD33-deficient stem cells
Vor Biopharma Inc. co-founder Siddhartha Mukherjee at Columbia University showed transplantation of hematopoietic stem cells with genetic ablation of CD33

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE